When was Curemark founded?

Curemark was founded in 2004 and raised its 1st funding round 5 years after it was founded.

Where is Curemark located?

Curemark is headquartered in New York City, United States. It is registered at 411 Theodore Fremd Avenue, Suite 206 Rye, NYC 10580.

How many employees does Curemark have?

As of Feb 28, 2026, the latest employee count at Curemark is 23.

Is Curemark a funded company?

Curemark is a funded company, having raised a total of $96M across 13 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Jun 19, 2009.

When was the latest funding round of Curemark?

Curemark's latest funding was a $***** Series B round on Jan 30, 2023, with participation from 0 investor.

Where does Curemark rank among its competitors?

Curemark ranks 10th amongst 38 active competitors, of which 13 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was SciNeuro, which secured $53M in Dec, 2025.

Who are the top competitors of Curemark?

Curemark's top competitors include Cingulate, SciNeuro and STALICLA. Among them, SciNeuro secured the most recent funding round in December, 2025.

Curemark - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of therapeutics for the treatment of Autism and other neurological diseases. The company offers biomarker and pancreatic enzyme products for diagnosing and treating children with autism spectrum disorders. It develops drugs for Autism, ADHD, Addiction, Parkinson’s Disease, and Schizophrenia.

Website: curemark.com
Social
Registered Address: 411 Theodore Fremd Avenue, Suite 206 Rye, NYC 10580

Key Metrics

Founded Year

2004

Location

New York City, United States

Stage

Series B

Total Funding

$96M in 13 rounds

Latest Funding Round

Series B, Jan 30, 2023, $*****

Investors

Grimley Capital & 2 more

Ranked

10^th among 38 active competitors

Employee Count

23 as on Feb 28, 2026

Similar Companies

Cingulate & 40 more

View Curemark's full profile

Curemark is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
CUREMARK HEALTH CARE PRIVATE LIMITED CIN: U85300BR2022PTC058364 , India, Active	Jun 09, 2022	$1.26M (As on Mar 31, 2024)	-
Curemark, Llc CIN: 20-5502322 , United States, Active	Jan 01, 2004	-	9 (As on Dec 31, 2021)	-

Curemark has raised a total funding of $96M over 13 rounds. Its first funding round was on Jun 19, 2009. Curemark has 3 institutional investors.

Here is the list of recent funding rounds of Curemark:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 30, 2023	9086302	Series B	8040373	1844939	8449507	3016612
Apr 14, 2021	6910076	Series B	5651193	4263338	7697432	6570591
Sep 11, 2019	6061728	Series B	8638937	6685991	6096701	5421860

Access funding benchmarks and valuations. Sign up today!

View details of Curemark's funding rounds and investors

The founders of Curemark is Joan Fallon.

Here are the details of Curemark's key team members:

Joan Fallon: Founder and CEO of Curemark.
Contact Info: 1 email address

View details of Curemark's Founder profiles and Board Members

Curemark's employee count trend

Curemark has 23 employees as of Feb 26. Here is Curemark's employee count trend over the years:

Uncover Curemark's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Curemark include Cingulate, SciNeuro and STALICLA. Here is the list of Top 10 competitors of Curemark, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Cingulate 2012, Kansas City (United States), Public	Developer of therapeutics for the treatment of ADHD	$33M	The Werth Family Foundation, Lincoln Park Capital ... & 2 others	58/100
2nd	SciNeuro 2020, Shanghai (China), Series A	Developer of therapeutic solutions for the treatment of CNS disorders	$153M	Arch Venture Partners, LAV & 6 others	56/100
3rd	STALICLA 2017, Geneva (Switzerland), Series B	Manufacturer of precision medicinea for neurodevelopmental disorders	$24.1M	Addex Therapeutics, SPRIM Global Investments ... & 7 others	56/100
4th	Abliva 2000, Lund (Sweden), Acquired	Developer of drugs to treat multiple neurological disorders	-	Hadean Ventures, IP Group & 2 others	53/100
5th	NEOS Therapeutics 2008, Grand Prairie (United States), Public	Speciality Company developing extended release drugs for CNS disorders using proprietary technology platform	$94.6M	Presidio Partners, Essex Capital & 7 others	50/100
6th	Scienture 2019, Hauppauge (United States), Public	Developer of therapeutics for CNS, oncology, and cardiovascular disease	-	-	48/100
7th	Connecta Therapeutics 2018, Barcelona (Spain), Seed	Developer of drugs for treating neurological disorders	$4.89M	Inveready, CDTI & 4 others	47/100
8th	Nura Bio 2018, San Francisco (United States), Series A	Provider of solution for diagnosis of a neurological disorder and neuroprotective medicines	$141M	The Column Group, Sanofi Ventures & 2 others	47/100
9th	Markit 2003, London (United Kingdom), Public	Developer of NMDA receptor modulators for neuropsychiatric and neurodevelopmental disorders	-	-	47/100
10th	Curemark 2004, New York City (United States), Series B	Developer of therapeutics for the treatment of Autism and other neurological diseases	$96M	Grimley Capital, Springboard Enterprises & 1 others	49/100